Awardee OrganizationBOSTON UNIVERSITY MEDICAL CAMPUS
Description
Abstract Text
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
In order to improve their pharmacological properties, heparins are partially depolymerized to produce low molecular weight heparin (LMWH) preparations. LMWHs have the advantage that they eliminate some heparin side effects by virtue of the fact that the have fewer undesired interactions with proteins in the blood stream. The pharmacological properties of LMWHs depend strongly on the method used in their depolymerization. As a result, there are more than a dozen LMWH drugs on the market world wide, each used for a specific clinical indication. Heparins and LMWH consist of a polymeric distribution of heparin chain. Chains of a given length are distribution of sulfation, acetylation and epimerization isomers. As a result, it is nearly impossible to fully characterize the structure of a heparin or LMWH preparation.
Effective tools for structural analysis of LMWH are needed to facilitate development of both new LMWH drugs and generics. Generic developers must prove that their LMWH preparations are structurall identical to the innovator material. The polydispersisty of LMWH make this a very challenging task. In many ways, this is similar to the problem of establishing sameness of recombinant glycoprotein drugs. The anticoagulant properties of LMWH depend on the levels of a particular oligosaccharide sequence containing a critical GlcN-3-sulfate group. This sequence has been shown to resist degradation by heparin lyase and to remain as a tetrasaccharide.
LMWH preparations were exhaustively digested using heparin lyases and then analyzed using amide-HILIC LC/MS. The results were used to compare the abundances of the most abundant di-, tri- and tetrasaccharide products in the LMWH digests. As expected, the most abundant disaccharides have two and three sulfate groups. LMWH depolymerized using nitrous acid (Dalteparins) show disaccharides with anhydromannitol on the formerly reducing end. Pentasulfated tetrasaccharides are also observed that contain the critical GlcN-3-O-sulfate group.
Public Health Relevance Statement
Data not available.
NIH Spending Category
Biotechnology
Project Terms
AcetylationAdverse effectsAmidesAnticoagulantsBloodClinicalComputer Retrieval of Information on Scientific Projects DatabaseDevelopmentDisaccharidesFundingGeneric DrugsGlycoproteinsGrantHeparinHeparin LyaseInorganic SulfatesInstitutionIsomerismLengthLow-Molecular-Weight HeparinMarketingMethodsNitrous AcidOligosaccharidesPharmaceutical PreparationsPreparationPropertyProteinsRecombinantsResearchResearch PersonnelResourcesSourceStreamStructureTrisaccharidesUnited States National Institutes of HealthUnspecified or Sulfate Ion Sulfatesdepolymerizationepimerizationimprovedliquid chromatography mass spectrometrysulfationtool
No Sub Projects information available for 5P41RR010888-12 5293
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5P41RR010888-12 5293
Patents
No Patents information available for 5P41RR010888-12 5293
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5P41RR010888-12 5293
Clinical Studies
No Clinical Studies information available for 5P41RR010888-12 5293
News and More
Related News Releases
No news release information available for 5P41RR010888-12 5293
History
No Historical information available for 5P41RR010888-12 5293
Similar Projects
No Similar Projects information available for 5P41RR010888-12 5293